Alicia Jackson, the Trump-appointed director of HHS's Advanced Research Projects Agency for Health, held at least $115,000 in stock in the menopause-treatment company Evernow, plus options of unknown value, when she spoke at the HHS press conference announcing the removal of black box warnings from hormone replacement therapy, according to her financial disclosures as reported by ProPublica on Nov. 13.

The Campaign Legal Center has filed a complaint with the HHS inspector general alleging a conflict of interest. The complaint also questions how Jackson identified up to $400 million in underlying assets in her husband's investment firm. Her disclosures list more than 60 venture capital and private equity funds, at least 13 managed by 137 Ventures, co-founded by her husband, Alex Jacobson.

Jackson was sworn in Oct. 20, 2025. ARPA-H has a $1.5 billion budget, with grants including $160 million for genetic medicines and rare diseases and $144 million for existing treatments for age-related illnesses. Two of her financial disclosures, filed last October and two months ago, remain uncertified. She has been placed on administrative leave; the reason has not been publicly explained.

ProPublica reports it is unclear what role Jackson played in the hormone therapy decision, and an FDA expert panel recommended ending the warning before she took office. HHS, Jackson, Jacobson and 137 Ventures did not comment to ProPublica.